ARCA biopharma, Inc. (ABIO) |
|
2.01 0 (0%)
|
10-02 15:59 |
|
Open: |
2.01 |
Pre. Close: |
2.01 |
|
High:
|
2.04 |
Low:
|
2 |
|
Volume:
|
36,399 |
Market Cap:
|
29(M) |
|
|
|
Technical analysis |
as of: 2023-10-02 4:48:01 PM |
|
Short-term rate:
|
 |
| Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
|
Mid-term rate:
|
|
| Target: |
Six months: 2.38 One year: 2.41 |
| Support: |
Support1: 1.99 Support2: 1.65 |
| Resistance: |
Resistance1: 2.03 Resistance2: 2.06 |
| Pivot: |
2.03  |
| Moving Average: |
MA(5): 2.01 MA(20): 2.03
MA(100): 2.05 MA(250): 2.1 |
| MACD: |
MACD(12,26): -0.1 Signal(9): -0.1 |
| Stochastic oscillator: |
%K(14,3): 4.7  %D(3): 2.5 |
| RSI: |
RSI(14): 42.1 |
| 52-week: |
High: 2.7 Low: 1.85 |
| Average Vol(K): |
3-Month: 20 (K) 10-Days: 20 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ ABIO ] has closed above bottom band by 25.9%. Bollinger Bands are 14.3% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
2.04 - 2.06 |
2.06 - 2.07 |
|
Low:
|
1.97 - 1.99 |
1.99 - 2 |
|
Close:
|
1.99 - 2.01 |
2.01 - 2.03 |
|
Company Description |
|
ARCA biopharma, Inc., a clinical-stage biopharmaceutical company, develops and commercializes genetically targeted therapies for cardiovascular diseases. Its lead product candidates are Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), which is in Phase IIb clinical trial for the treatment for COVID-19; and Gencaro (bucindolol hydrochloride), a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase IIb trial for the treatment of atrial fibrillation in patients with chronic heart failure. ARCA biopharma, Inc. has a collaboration agreement with LabCorp to develop genetic test for GENETIC-AF clinical trial; and research collaboration with Colorado Prevention Center, the University of Colorado's Academic Research Organization to develop and commercialize Gencaro. The company was incorporated in 2004 and is headquartered in Westminster, Colorado. |
Headline News |
Mon, 02 Oct 2023
ARCA biopharma, Inc. (NASDAQ:ABIO) Short Interest Up 9.5% in ... - Defense World
Fri, 21 Jul 2023
ARCA biopharma Announces Second Quarter 2023 Financial Results - GlobeNewswire
Mon, 19 Dec 2022
James Flynn Joins ARCA biopharma Board of Directors - BioSpace
Tue, 21 Jun 2022
Jacob Ma-Weaver Joins ARCA biopharma Board of Directors - GlobeNewswire
Thu, 05 May 2022
ARCA biopharma Retains Ladenburg Thalmann to Support ... - GlobeNewswire
Mon, 18 Apr 2022
ARCA biopharma Establishes Special Committee of the Board of ... - GlobeNewswire
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Neutral |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
14 (M) |
| Shares Float |
9 (M) |
|
% Held by Insiders
|
1 (%) |
|
% Held by Institutions
|
45.2 (%) |
|
Shares Short
|
242 (K) |
|
Shares Short P.Month
|
254 (K) |
Stock Financials |
|
EPS
|
-0.44 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
2.72 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
-9.8 |
|
Return on Equity (ttm)
|
-15.1 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
-0.49 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-6 (M) |
|
Levered Free Cash Flow
|
-4 (M) |
Stock Valuations |
|
PE Ratio
|
-4.57 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0.73 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
-4.62 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
